Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States



Survival: 8.7 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: New York, NY
   
Hospital: Memorial Sloan-Kettering Cancer Center
   
Journal: Link
   
Date: 8/2014

Description:
Patients:
This phase 2 study involved metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 52 patients with a median age 63.0 years and 71.2% male. Group B had 50 patients with a median age of 61.5 years and 76.0% male.

Treatment:
Patients in group A received biologic therapy with ramucirumab (a monoclonal antibody that inhibits cancer growth signals to the VEGF protein) and chemotherapy with dacarbazine.

Patients in group B received biologic therapy with ramucirumab only.

Toxicities:
Treatment-related death of one patient due to heart attack was reported for group A. Grade 3 fatigue and grade 4 neutropenia and thrombocytopenia were also reported.

Treatment-related death of one patient due to heart attack was reported for group B. Grade 4 thrombocytopenia and infusion-related reactions were also reported.

Results:
The median overall survival for groups A and B was 8.7 and 11.1 months, respectively.

Support:
This study was supported by ImClone Systems, LLC.

Correspondence: Dr. Richard D. Carvajal; email: carvajar@mskcc.org

E-mail to a Friend Email Physician More Information